Application of Shengxuening tablets for the prevention of anemia in pregnancy: stratified efficacy analysis based on serum ferritin levels and thalassemia subgroups

SXN tablets effectively ameliorate ID and anemia in both the general obstetric population and pregnant women with the thalassemia trait. The greatest benefit occurs when prophylaxis is initiated at baseline SF ≥30 μg/L. Baseline SF levels positively correlate with therapeutic response, indicating that adequate iron reserves enhance treatment efficacy. Routine, guideline-based iron supplementation should remain a cornerstone of antenatal care; however, individualized regimens tailored to initial iron status warrant further investigation.